A peer-reviewed paper detailing the experimental cancer treatment developed by Professor Georgina Long AO, University of Sydney medical oncologist and Medical Director of the Melanoma Institute Australia, has today been published in Nature Medicine, paving the way for a clinical trial to be conducted by researchers at the Brain Cancer Centre in Melbourne.
2025
Immunotherapy Combinations Reign Supreme in Upfront Melanoma Management
Teresa Petrella, MD, MHSc, FRCPC, discusses long-term data that inform the sequencing of immunotherapy and targeted therapies for frontline melanoma.
7-Year Follow-up of ABC Trial: Ipilimumab/Nivolumab vs Nivolumab Alone in Melanoma Brain Metastases
As reported in The Lancet Oncology by Long et al, 7-year follow-up of the Australian phase II ABC trial showed continued benefit of ipilimumab/nivolumab vs nivolumab alone in patients with asymptomatic melanoma brain metastases.
Cost-of-Care Discussions Between Cancer Patients & Providers
Most physicians agree that patients should know how much they’re going to pay for treatment before deciding on a plan. According to a survey of breast cancer surgeons, 87 percent agreed with this. Yet, it’s only a minority of physicians who claim they have cost-of-care discussions with their patients.